PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33904646-9 2021 IMPLICATIONS FOR PRACTICE: Using data from the FIRSTANA and PROSELICA phase III clinical trials we demonstrate that patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or cabazitaxel, who exhibited a response (pain, tumor, PSA), often experienced significantly greater improvements in health-related quality of life (HRQL) compared with patients without a response. cabazitaxel 209-220 kallikrein related peptidase 3 Homo sapiens 261-264 34450475-5 2021 The relationships between baseline NLR (< versus >= median (3.38)) and rPFS, OS, time to prostate-specific antigen progression, and prostate-specific antigen response to cabazitaxel versus ARTA were evaluated using Kaplan-Meier estimates. cabazitaxel 170-181 kallikrein related peptidase 3 Homo sapiens 132-157 34110449-6 2021 Analysis of the variables after 3 cycles of cabazitaxel, however, revealed two factors, PSA decline > 30% (p = 0.016) and neutrophil-lymphocyte ratio (NLR) decline > 30% (p = 0.044), as the predictors of favorable outcome for OS. cabazitaxel 44-55 kallikrein related peptidase 3 Homo sapiens 88-91 34110449-9 2021 CONCLUSIONS: This is the first study to demonstrate that PSA and NLR decline 3 cycles after the initiation of cabazitaxel were associated with favorable outcome in patients with CRPC. cabazitaxel 110-121 kallikrein related peptidase 3 Homo sapiens 57-60 34219125-0 2021 Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report. cabazitaxel 59-70 kallikrein related peptidase 3 Homo sapiens 10-35 29636272-13 2018 The level of prostate-specific antigen decreased by >= 50% in 24% of patients at rechallenge (71% with initial CABA). cabazitaxel 114-118 kallikrein related peptidase 3 Homo sapiens 13-38 32970933-14 2021 Patients with mCRPC who received >=4 cycles of CBZ showed a >=30% reduction in the serum PSA levels, and did not have visceral metastasis might achieve longer OS. cabazitaxel 47-50 kallikrein related peptidase 3 Homo sapiens 89-92 31931827-6 2020 After the third cycle of cabazitaxel, his prostate-specific antigen level was stable at < 10 ng/mL, and no radiological progression was detected. cabazitaxel 25-36 kallikrein related peptidase 3 Homo sapiens 42-67 31461725-10 2019 Improvements in aBSI and PSA after 16 weeks of cabazitaxel occurred in 7 (21.9%) and 12 patients (37.5%), respectively. cabazitaxel 47-58 kallikrein related peptidase 3 Homo sapiens 25-28 30283980-5 2018 Twenty (42.6%) were judged to have responded to cabazitaxel with a PSA decrease >= 30% from the baseline. cabazitaxel 48-59 kallikrein related peptidase 3 Homo sapiens 67-70 30283980-6 2018 A 30% PSA response to cabazitaxel was achieved in 4 (50.0%) patients with 75 years (n = 8) and 16 (41.0%) patients with less than 75 years (n = 39). cabazitaxel 22-33 kallikrein related peptidase 3 Homo sapiens 6-9 30283980-8 2018 A 30% PSA response to cabazitaxel was achieved in 13 (46.4%) and 7 (36.8%) patients with and without that to docetaxel, respectively. cabazitaxel 22-33 kallikrein related peptidase 3 Homo sapiens 6-9 30283980-9 2018 A 30% PSA response to cabazitaxel was achieved in 5 (16.6%) and 7 (41.2%) patients who had treated with less than 10 cycles docetaxel or 10 cycles, respectively. cabazitaxel 22-33 kallikrein related peptidase 3 Homo sapiens 6-9 31892584-5 2020 PSA response, progression-free survival, and overall survival in cabazitaxel chemotherapy were comparable between patients with and without prior use of ARAT agents. cabazitaxel 65-76 kallikrein related peptidase 3 Homo sapiens 0-3 31361807-14 2019 Cabazitaxel was also effective in terms of the PSA response, OS, and TTF. cabazitaxel 0-11 kallikrein related peptidase 3 Homo sapiens 47-50 31369101-0 2019 Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer. cabazitaxel 51-62 kallikrein related peptidase 3 Homo sapiens 0-25 31570485-7 2019 CONCLUSION: Patients with anemia, high PSA, and lower number of docetaxel therapy cycles might have shorter survival period from introduction of cabazitaxel therapy. cabazitaxel 145-156 kallikrein related peptidase 3 Homo sapiens 39-42 31570485-8 2019 In addition, PSA decline might still be a useful indicator as a predictor of prognosis of the metastatic CRPC patients treated with cabazitaxel. cabazitaxel 132-143 kallikrein related peptidase 3 Homo sapiens 13-16 31185946-13 2019 After 2 cycles of CBZ chemotherapy, PSA level decreased to < 0.01 ng/mL and the lung metastases completely disappeared, with a reduced CTC count of < 5. cabazitaxel 18-21 kallikrein related peptidase 3 Homo sapiens 36-39 29305637-0 2018 PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study. cabazitaxel 16-27 kallikrein related peptidase 3 Homo sapiens 0-3 29305637-1 2018 PURPOSE: To evaluate the association between prostate-specific antigen (PSA) response and progression-free and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel. cabazitaxel 209-220 kallikrein related peptidase 3 Homo sapiens 72-75 29305637-10 2018 CONCLUSION: PSA response after four cycles of cabazitaxel is associated with improved progression-free survival in men with mCRPC treated with cabazitaxel plus prednis(ol)one. cabazitaxel 46-57 kallikrein related peptidase 3 Homo sapiens 12-15 29305637-10 2018 CONCLUSION: PSA response after four cycles of cabazitaxel is associated with improved progression-free survival in men with mCRPC treated with cabazitaxel plus prednis(ol)one. cabazitaxel 143-154 kallikrein related peptidase 3 Homo sapiens 12-15 27618249-3 2017 Primary outcome was change in QoL (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item) with respect to prostate-specific antigen (PSA) response after four cycles of cabazitaxel. cabazitaxel 211-222 kallikrein related peptidase 3 Homo sapiens 149-180 22445962-0 2012 Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report. cabazitaxel 0-11 kallikrein related peptidase 3 Homo sapiens 27-52 27057826-2 2016 Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient"s performance status had improved to 1, the hemoglobin level was 12.9 g/dL and his serum prostate specific antigen levels were reduced by >70%, with no treatment-related adverse events.Although docetaxel rechallenge is a therapeutic option for selected patients, the risk of cumulative toxicity described in literature must be carefully considered.As the risk of cabazitaxel-related cumulative toxicity is probably lower, retreatment with cabazitaxel rather than docetaxel may also be an option in the setting of heavily pretreated mCRPC patients. cabazitaxel 312-323 kallikrein related peptidase 3 Homo sapiens 481-506 27057826-2 2016 Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient"s performance status had improved to 1, the hemoglobin level was 12.9 g/dL and his serum prostate specific antigen levels were reduced by >70%, with no treatment-related adverse events.Although docetaxel rechallenge is a therapeutic option for selected patients, the risk of cumulative toxicity described in literature must be carefully considered.As the risk of cabazitaxel-related cumulative toxicity is probably lower, retreatment with cabazitaxel rather than docetaxel may also be an option in the setting of heavily pretreated mCRPC patients. cabazitaxel 758-769 kallikrein related peptidase 3 Homo sapiens 481-506 27057826-2 2016 Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient"s performance status had improved to 1, the hemoglobin level was 12.9 g/dL and his serum prostate specific antigen levels were reduced by >70%, with no treatment-related adverse events.Although docetaxel rechallenge is a therapeutic option for selected patients, the risk of cumulative toxicity described in literature must be carefully considered.As the risk of cabazitaxel-related cumulative toxicity is probably lower, retreatment with cabazitaxel rather than docetaxel may also be an option in the setting of heavily pretreated mCRPC patients. cabazitaxel 758-769 kallikrein related peptidase 3 Homo sapiens 481-506 26829012-5 2016 The relationships with prostate-specific antigen (PSA) responses during cabazitaxel therapy and baseline NLR were also analysed. cabazitaxel 72-83 kallikrein related peptidase 3 Homo sapiens 23-54 24255983-9 2014 However, patients treated with second line cabazitaxel had an inferior PSA response to enzalutamide (p = 0.03), and there was a trend for the PSA response to abiraterone to correlate with the PSA response to the succeeding enzalutamide (B = 0.22, p = 0.05). cabazitaxel 43-54 kallikrein related peptidase 3 Homo sapiens 71-74 23532557-3 2013 In addition, progression-free survival, the times to tumour progression and prostate specific antigen (PSA) progression, and tumour and PSA response rates were improved with cabazitaxel plus prednisone. cabazitaxel 174-185 kallikrein related peptidase 3 Homo sapiens 76-101 23532557-3 2013 In addition, progression-free survival, the times to tumour progression and prostate specific antigen (PSA) progression, and tumour and PSA response rates were improved with cabazitaxel plus prednisone. cabazitaxel 174-185 kallikrein related peptidase 3 Homo sapiens 103-106 23532557-3 2013 In addition, progression-free survival, the times to tumour progression and prostate specific antigen (PSA) progression, and tumour and PSA response rates were improved with cabazitaxel plus prednisone. cabazitaxel 174-185 kallikrein related peptidase 3 Homo sapiens 136-139 27960186-5 2017 RESULTS: Cabazitaxel was well tolerated, showing a manageable toxicity profile, associated with a modest objective response rate and a good reduction in PSA levels. cabazitaxel 9-20 kallikrein related peptidase 3 Homo sapiens 153-156 24411987-5 2014 OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Changes in prostate-specific antigen (PSA) level were used to determine activity on abiraterone, enzalutamide, and cabazitaxel treatment. cabazitaxel 162-173 kallikrein related peptidase 3 Homo sapiens 58-89 24725337-0 2014 Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. cabazitaxel 43-54 kallikrein related peptidase 3 Homo sapiens 0-25 22933996-7 2012 Cabazitaxel was initiated in October 2010; his condition stabilized within weeks, and he experienced a progressive decline in his PSA level from a peak of 5,424 ng/ml. cabazitaxel 0-11 kallikrein related peptidase 3 Homo sapiens 130-133 22933996-9 2012 After 16 cycles of cabazitaxel, his PSA declined to 994 ng/ml as of January 2012. cabazitaxel 19-30 kallikrein related peptidase 3 Homo sapiens 36-39